Tau antibody therapy is effective in transgenic mice but the mechanisms of tau clearance are not well known. To this end, tau antibody uptake was analyzed in brain slice cultures and primary neurons. Internalization was rapid (<1h), saturable, and substantial compared to control mouse IgG. Furthermore, temperature reduction to 4°C, excess of unlabeled mouse IgG, or excess tau antibodies reduced uptake in slices by 63%, 41%, and 62% respectively (p=0.002, 0.04, 0.005). Uptake strongly correlated with total and insoluble tau levels (r2=0.77 and 0.87, p=0.002 and 0.0002), suggesting that tau aggregates influence antibody internalization and/or retention within neurons. Inhibiting phagocytosis did not reduce... More
Tau antibody therapy is effective in transgenic mice but the mechanisms of tau clearance are not well known. To this end, tau antibody uptake was analyzed in brain slice cultures and primary neurons. Internalization was rapid (<1h), saturable, and substantial compared to control mouse IgG. Furthermore, temperature reduction to 4°C, excess of unlabeled mouse IgG, or excess tau antibodies reduced uptake in slices by 63%, 41%, and 62% respectively (p=0.002, 0.04, 0.005). Uptake strongly correlated with total and insoluble tau levels (r2=0.77 and 0.87, p=0.002 and 0.0002), suggesting that tau aggregates influence antibody internalization and/or retention within neurons. Inhibiting phagocytosis did not reduce uptake in slices or neuronal cultures, indicating limited microglial involvement. In contrast, clathrin specific inhibitors reduced uptake in neurons (≤ 78%, p<0.0001) and slices (≤ 35%, p=0.03), demonstrating receptor-mediated endocytosis as the primary uptake pathway. Fluid phase endocytosis accounted for the remainder of antibody uptake in primary neurons, based on co-staining with internalized dextran. The receptor-mediated uptake is to large extent via low affinity FcγII/III receptors, and can be blocked in slices (43%, p=0.04) and neurons (53%, p=0.008) with an antibody against these receptors. Importantly, antibody internalization appears to be necessary for tau reduction in primary neurons. Overall, these findings clarify that tau antibody uptake is primarily receptor-mediated, that these antibodies are mainly found in neurons with tau aggregates, and that their intracellular interaction leads to clearance of tau pathology, all of which have major implications for therapeutic development of this approach.
